Found in the transcript:
"With this, we are well on the way to building the sustainable biopharmaceutical company focused on serving patient needs at the intersection of pulmonary orphan and infectious diseases."
This is why I hope someone doesn't try to buy Insmed. With my minimal shares, I would vote NO!!